CD19 and neuromyelitis optica: The use of CD19 + (a pan B-cell marker) monitoring in NMO was initially suggested but the incidence of NMO relapses occurring even at low levels of CD19 + B-cell repopulation suggests this approach may compromise disease control [9, 11].